Waldenström macroglobulinemia: My way

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Waldenström macroglobulinemia is a lymphoplasmacytic lymphoma. A serum monoclonal IgM protein is required to establish this diagnosis. The clinical features patients develop include normochromic normocytic anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy and signs of hyperviscosity. The International Staging System for Waldenstr m macroglobulinemia divides patients prognostically based on age, hemoglobin, platelet count, IgM level, and β2 microglobulin. Some patients with Waldenstr m macroglobulinemia have a smoldering form and can be observed without intervention. Active agents in the treatment of Waldenstr m macroglobulinemia include rituximab, chlorambucil, cyclophosphamide, fludarabine, bortezomib, lenalidomide, bendamustine, everolimus, and alemtuzumab. The current preferred Mayo Clinic non-study treatment is rituximab, cyclophosphamide, and dexamethasone. The median survival associated with this disease is now over 10 years.

Original languageEnglish (US)
Pages (from-to)464-471
Number of pages8
JournalLeukemia and Lymphoma
Issue number3
StatePublished - Mar 1 2013


  • Chemotherapy
  • Macroglobulinemia
  • Prognosis
  • Waldenström

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Waldenström macroglobulinemia: My way'. Together they form a unique fingerprint.

Cite this